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Recent research suggests that melatonin (Mel), an endogenous hormone and natural supplement, possesses anti- 
proliferative effects and can sensitise cells to anti-cancer therapies. Although shikonin (SHK) also possesses 
potential anti-cancer properties, the poor solubility and severe systemic toxicity of this compound hinders its 
clinical usage. In this study, we combined Mel and SHK, a potentially promising chemotherapeutic drug com-
bination, with the aim of reducing the toxicity of SHK and enhancing the overall anti-cancer effects. We 
demonstrate for the first time that Mel potentiates the cytotoxic effects of SHK on cancer cells by inducing 
oxidative stress via inhibition of the SIRT3/SOD2-AKT pathway. Particularly, Mel-SHK treatment induced 
oxidative stress, increased mitochondrial calcium accumulation and reduced the mitochondrial membrane po-
tential in various cancer cells, leading to apoptosis. This drug combination also promoted endoplasmic reticulum 
(ER) stress, leading to AKT dephosphorylation. In HeLa cells, Mel-SHK treatment reduced SIRT3/SOD2 
expression and SOD2 activity, while SIRT3 overexpression dramatically reduced Mel-SHK-induced oxidative 
stress, ER stress, mitochondrial dysfunction and apoptosis. Hence, we propose the combination of Mel and SHK 
as a novel candidate chemotherapeutic regimen that targets the SIRT3/SOD2-AKT pathway in cancer.   
1. Introduction 
The incidence of cancer and associated mortality is increasing 
rapidly worldwide, with an estimated 18 million new cases and 9.5 
million cancer-related deaths in 2018 [1]. Although surgery, chemo-
therapy, and radiotherapy are the mainstays of cancer treatment, elderly 
patients and those with advanced-stage cancer experience a worse 
prognosis, more adverse effects, and increased tumour recurrence [2]. 
To address these challenges, improvements in existing chemotherapies 
and treatments that target specific oncogenic pathways are needed. In 
one promising approach, natural compounds known to possess 
anti-cancer properties could be potentiated when combined with 
non-toxic dietary supplements to minimise toxicity and enhance 
anti-cancer efficacy. 
The hormone melatonin (Mel, N-acetyl-5-methoxytryptamine), pre-
viously thought to be secreted only by the pineal gland, is now known to 
be synthesised by the mitochondria in every cell of almost every organ of 
the body [3]. Interestingly, artificial night-time light disrupts Mel pro-
duction and the normal circadian rhythm, which is reported to 
contribute to the initiation, promotion, and progression of cancers [4,5]. 
The endogenous production and virtually non-toxic nature of Mel render 
it an ideal chemotherapeutic option. Shikonin (SHK), an active natural 
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plant extracts, has recently attracted much attention in the development 
of new anti-cancer therapeutic strategies [6]. In particularly, SHK in-
duces reactive oxygen species (ROS), which play upstream roles in 
mitochondria-mediated apoptosis and cancer cell death [7,8]. Unfortu-
nately, the poor solubility and severe systemic toxicity of SHK hinder its 
clinical use as an anti-cancer drug [9]. Although recent studies have 
demonstrated that combinations of Mel with various anti-cancer drugs 
sensitised cancer cells and enhanced apoptosis by reducing cell viability 
and growth [10–12], the anti-cancer effects of Mel combined with SHK 
have never been explored. 
Sirtuin-3 (SIRT3) regulates intracellular metabolism mainly by 
modulating mitochondrial oxidative stress [13]. In mitochondria, SIRT3 
primarily deacetylates stress-responsive proteins and regulates mito-
chondrial membrane integrity and energy homeostasis [14]. Addition-
ally, SIRT3 regulates superoxide dismutase 2 (SOD2) by deacetylating 
and activating the SOD2 transcription factor FOXO3a, or by directly 
deacetylating and activating SOD2 dismutase activity. SOD2 then ca-
talyses the neutralisation of superoxide conversion into water and 
hydrogen peroxide [15,16]. Decreased SIRT3 expression enhances 
ROS-mediated oxidative damage, suggesting that SIRT3 inhibitors may 
be therapeutically beneficial. Furthermore, studies demonstrating the 
role of SIRT3-induced apoptosis in cancer cells [17,18] suggest that 
combinations such as Mel and SHK might function via inhibition of the 
SIRT3-SOD2 pathway to induce cancer cell death. 
In this study, we explored the ability of Mel to augment the anti- 
cancer effect of SHK. We demonstrated, for the first time, that Mel- 
SHK induced endoplasmic reticulum (ER) stress and increased ROS 
production by inhibiting the SIRT3-SOD2 and AKT pathway, and 
reduced cell growth and survival in various cancers. 
2. Materials and methods 
2.1. Chemicals and inhibitors 
Mel, SHK, N-acetyl-cysteine (NAC, ROS scavenger), 4-Bromo-Resver-
atrol (4-BR, SIRT inhibitor), N-Benzyloxycarbonyl-Val-Ala-Asp(O–Me) 
fluoromethyl ketone (Z-VAD-FMK, caspase inhibitor), 4-phenylbutyric 
acid (4-PBA, ER stress inhibitor), LY 294002 (PI3K inhibitor), 
Necrostatin-1 (Nec-1, a specific inhibitor of RIP1 kinase), necrosulfo-
namide (NSA, a specific inhibitor of necrosis downstream of RIP3 acti-
vation), U0126 (MEK-1/2 inhibitor), a JNK inhibitor (JNK-IN-8) and a 
p38 inhibitor (SB203580) were all purchased from Sigma-Aldrich (St. 
Louis, MO, USA) and were solubilised as recommended. 
2.2. Cell culture and treatment 
A human histiocytic lymphoma (U937; RRID: CVCL_0007) cell line 
was obtained from the Human Sciences Research Resources Bank 
(Tokyo, Japan) and was cultured using RPMI-1640 medium, supple-
mented with 10% heat-inactivated fetal bovine serum (FBS) at 37 �C, in 
humidified air with 5% CO2. Additionally, human papillomavirus- 
related endocervical adenocarcinoma (HeLa; RRID: CVCL_0030), 
human hepatoblastoma (Hep-G2; RRID: CVCL_0027), human gastric 
cancer (AGS; RRID: CVCL_0139), human breast adenocarcinoma (MCF- 
7; RRID: CVCL_0031), human colon adenocarcinoma (SW480; RRID: 
CVCL_0546), human lung adenocarcinoma (A549; RRID: CVCL_0023), 
baby hamster kidney fibroblasts (BHK; RRID: CVCL_ 1915), murine 
fibroblast (NIH3T3; RRID: CVCL_0594), and human skin keratinocytes 
(HaCaT; RRID: CVCL_0058) cell lines were obtained from the Japan 
Cancer Research Resources Bank (Tokyo, Japan). African green monkey 
kidney (Vero; ATCC: CCL_81) cells were obtained from the American 
Type Culture Collection (Manassas, VA, USA). All the cell lines were 
mycoplasma-free cells and were authenticated using short tandem 
repeat (STR) genotyping within the last three years and were verified to 
be identical with the STR profile in comparing databases. These cells 
were grown in RPMI-1640 or Dulbecco’s Modified Eagle’s Medium 
(DMEM), containing 10% heat-inactivated FBS, and maintained in a 
humidified incubator at 37 �C with 5% CO2. U937 and HeLa cells were 
used more extensively, and target molecules and pathways were inves-
tigated mainly in the latter. Cells were seeded into dishes or plates 
overnight according to experimental requirements, and were treated 
with the indicated concentrations of SHK with or without Mel. Inhibitors 
were pre-treated for 1 h before co-treatment with SHK and Mel. 
2.3. MTT assay 
The MTT (3-4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium 
bromide) assay was used to evaluate cell viability. Cells were seeded into 
96-well plates at 4 � 103 cells/well overnight. Briefly, MTT (5 mg/mL) 
solution was added to 96-well plates at 20 μL/well followed by incu-
bation for 4 h at 37 �C, and DMSO (dimethyl sulfoxide) was added at 150 
μL/well. The absorbance was measured at 490 nm on a microplate 
reader as reported previously [19]. Eight parallel wells were used for 
each concentration. 
2.4. Lactate dehydrogenase (LDH)-based cytotoxicity assay 
The cytotoxicity was measured by quantitating the release of LDH. 
Following incubation, the media was collected and centrifuged for 5 
min. The supernatants were collected and added to a 96-well plate at 50 
μL per well for LDH measurements, and then reaction buffer was added 
at the same volume. The assay plates were then incubated at room 
temperature in the dark for 20 min. Finally, 100 μL of stop buffer 
(diluted with PBS at 1:1) was added to each of the assay wells. The total 
volume in each well was 200 μL. The absorbance was measured at 570 
nm on a microplate reader, as reported previously [20]. 
2.5. Assessment of DNA fragmentation 
The cells were harvested 6 h after the treatment, and lysed with 200 
μL of lysis buffer (10 mmol/L Tris, 1 mmol/L EDTA, and 0.1% NP-40, pH 
7.5) and centrifuged at 13,000 g for 10 min to separate intact from 
fragmented chromatin. The supernatant-containing fragmented DNA 
and the pellet were precipitated overnight at 4 �C in 12.5% trichloro-
acetic acid (TCA). The DNA precipitates were hydrolysed by heating to 
90 �C for 20 min in 5% TCA overnight. For quantification of the frag-
mented DNA, the absorbance at 600 nm was measured (Beckman DU-50 
Spectrophotometer; Beckman Coulter, Brea, CA, USA) with diphenyl-
amine (DPA) reagent (0.15 g DPA, 0.15 mL H2SO4, and 0.05 mL acet-
aldehyde per 10 mL glacial acetic acid). “Percent fragmentation” refers 
to the ratio of DNA in the supernatant (“fragmented”) to the total DNA 
recovered in both the supernatant and pellet (“fragmented plus intact”). 
2.6. Drug combination assays 
Drug combinations were evaluated using the combination index (CI) 
method described by Chou and Talalay [21,22]. Briefly, the data of cell 
viability, as evaluated above, were analysed using CompuSyn software 
(ComboSyn, Inc., Paramus, NJ, USA) [21] to calculate the synergy be-
tween Mel and SHK (Mel:SHK ¼ 2:1 in U937, AGS cells; 1:2 in HeLa, 
MCF7, A549 cells; 1:4 in HepG2 cells; and 1:1 in SW480 cells). The 
resulting CI theorem of Chou-Talalay offers a quantitative definition for 
additive effect (CI ¼ 1), synergism (CI < 1), and antagonism (CI > 1) in 
drug combinations. 
2.7. IC50 shift assays 
The IC50 shift assay was used to determine the IC50 (i.e., the drug 
concentration that results in a 50% inhibition of activity) following SHK 
treatment, in the absence and presence of Mel. Briefly, cells were treated 
with various concentrations of SHK or co-treated with 2 mM Mel. After 
6 h (U937) or 24 h, cellular inhibition was calculated. The curve-fit lines 
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were generated using a non-linear curve fitting (regression) analysis in 
GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA) and the IC50 
shift was calculated. 
2.8. Apoptosis detection with flow cytometry 
The cells were harvested after 24 h of treatment and stained with 
fluorescein isothiocyanate-labelled annexin V (Annexin V/FITC) and 
propidium iodide (PI) for 30 min, prior to being analysed using a flow 
cytometry according to the manufacturer’s instructions. 
2.9. Cell colony formation 
Cells (2 � 102 per well) were seeded in 6-well plates and were 
cultivated in indicated media for 10–14 days after treatment. Subse-
quently, the media was removed, cells were washed twice in PBS and 
were fixed using 4% paraformaldehyde for 1 h and stained with crystal 
violet for 40 min at room temperature. Plates were thoroughly washed 
with water and air-dried at room temperature. 
2.10. Western blotting and immunoprecipitation (IP) 
After the desired treatment, cells were washed with PBS three times, 
and the total protein was extracted using RIPA lysis buffer or IP buffer 
containing protease and phosphatase inhibitors. The cell extracts were 
centrifuged at 13,000 rpm at 4 �C for 15 min. The supernatants were 
transferred to 1.5 mL Eppendorf tubes. The concentrations of the pro-
teins were measured using the Bradford Protein Assay Kit at 560 nm on a 
microplate reader. Twenty micrograms of protein per sample were 
electrophoresed at 18 mA for 90 min, followed by transfer to PVDF 
membranes (MilliporeSigma, Burlington, MA, USA) at 15 V, 0.15 A for 
90 min. Next, the membranes were blocked in 5% nonfat milk in TBST 
(150 mM NaCl, 50 mM Tris at pH 7.5, 0.1% Tween-20) for 2 h, and the 
specific primary antibody was incubated overnight at 4 �C. After TBST 
washing, the horseradish peroxidase (HRP)-labelled secondary antibody 
was added for 2 h at room temperature. Finally, the target proteins were 
detected using an enhanced chemiluminescent (ECL) kit (Amersham 
Biosciences, Buckinghamshire, UK) in accordance with the manufac-
turer’s instructions. The band densities were measured using Image 
Studio Lite (LI-COR Biosciences, Lincoln, NE, USA). 
2.11. Detection of ROS levels 
Alterations in the ROS levels were determined by dihydroethidium 
(DHE) staining (Molecular Probes, Eugene, OR, USA), which exhibits 
blue-fluorescence in the cytosol and can be oxidized by ROS in cells to 
form ethidium oxide, which can be incorporated into chromosomal DNA 
to produce red-fluorescent. Briefly, the cells were incubated with 4 μM 
DHE for 15 min at 37 �C. After washing twice with PBS, the population 
of ethidium bromide-stained cells was measured using FACS Canto II 
(EPICS XL, Beckman-Coulter, Miami, FL, USA and FACS Canto II, BD 
Biosciences, Mississauga, ON, USA) as the fraction of cells producing 
intracellular ROS, according to the manufacturer’s protocol. 
2.12. SOD2 activity 
SOD2 activity was measured using the SOD Assay kit and a water- 
soluble tetrazolium salt (WST)-1 as a substrate, in accordance with the 
manufacturer’s protocol (Dojindo Molecular Technology, Kumamoto, 
Japan). Briefly, the SOD activity of each immunoprecipitated protein 
was indicated by the inhibition of the WST-1 reduction rate. Potassium 
cyanide (1 mM) was added to the lysate (10 μg of total protein) during 
the assay to inhibit SOD1 and SOD3. Absorbance was measured at 450 
nm on a microplate reader, as reported previously [23]. 
2.13. Estimation of mitochondrial free calcium ions 
The calcium probe Rhod 2-AM (Sigma-Aldrich, St. Louis, MO, USA) 
was used to determine the effects of individual and combined treatments 
on mitochondrial calcium homeostasis. Cells were harvested after 12 h 
of treatment and were stained with 5 μM Rhod 2-AM for 30 min. The 
calcium fluorescence intensity was measured using a flow cytometry at 
excitation and emission maxima of 557 and 581 nm, respectively. 
2.14. Sub-G1 analysis 
Cells were harvested after 24 h of treatment and centrifuged at 
200�g at room temperature for 5 min. Cell pellets were suspended in 
100 μL PBS, fixed with 75% (v/v) cold ethanol for 2 h and stained with a 
PI solution containing DNase-free RNase A for 30 min at room temper-
ature in the dark. Cells were analysed using a flow cytometry according 
to the manufacturer’s instructions. 
2.15. Mitochondrial membrane potential 
Tetramethylrhodamine methyl ester perchlorate (TMRM) is a 
cationic fluorophore used widely to stain the mitochondria and mito-
chondrial matrices. Cells were harvested at an indicated time after 
treatment and exposed to 10 nM TMRM (Molecular Probes, Eugene, 
Oregon, USA) in 1 mL of PBS plus 1% FBS for 15 min at 37 �C. The 
percentage of cells with a low mitochondrial membrane potential 
(MMP) was detected by flow cytometry according to the manufacturer’s 
instructions. 
2.16. Wound healing assay 
Cells (3 � 105 per well) were seeded in 6-well plates overnight to 
ensure at least 90% confluency. Then, the cellular layer was scratched 
with a sterile micropipette tip (200 μL) to create a free-cell area. Non- 
adherent cells were washed three times using an FBS-free medium. 
The migration distance was measured on the images captured at 24 h, 48 
h and 72 h after SHK treatment with or without Mel using Image J 
software (National Institute for Health, Bethesda, MD, USA). The 
migration rate (MR) was calculated as [(A   B)/A] � 100, where A is the 
width at 0 h, and B is the width of indicated time at 24 h, 48 h and 72 h, 
respectively. 
2.17. Immunofluorescence 
Cells were seeded on glass coverslips. After treatment, the cells were 
incubated with an anti-SIRT3 or anti-SOD2 antibody overnight at 4 �C 
and stained with an Alexa Fluor 647-conjugated goat anti-rabbit sec-
ondary antibody. Nuclei were counterstained with Hoechst 33258. 
Immunofluorescence images were acquired using an LSM 780 confocal 
microscope (Carl Zeiss AG, Oberkochen, Germany). 
2.18. Plasmids and transfection 
The SIRT3-Flag plasmid was purchased from Addgene (Watertown, 
MA, USA). HeLa cells cultured in DMEM for 24 h were transfected with a 
SIRT3-Flag plasmid using the Amaxa® Cell Line Nucleofector® Kit ac-
cording to the manufacturer’s instructions. After 24 h, cells were pro-
cessed for immunoblotting and other assays according to the above- 
described experimental requirements. 
2.19. Statistical analysis 
All experiments were performed in biologically independent tripli-
cates. Data are presented as means � standard errors of the means 
(SEM). Statistical analyses were performed using CompuSyn and 
GraphPad Prism 5. The values of R (CompuSyn) and R2 (Graphpad) were 
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used to describe the goodness-of-fit of linear and non-linear regression 
trend lines, respectively. Image J was used to calculate the relative 
protein expression from Western blot images. Analyses of different 
treatment groups were performed by one-way analysis of variance 
(ANOVA) or two-way ANOVA using Tukey’s post hoc test. A value of P 
< 0.05 was considered statistically significant. 
3. Results 
3.1. Mel-SHK-induced anti-cancer activity and SIRT3-SOD2 
downregulation in U937 cells 
U937 cells were treated with varying levels of SHK (0–0.9 μM) and 
Mel (0–2 mM), the latter had no obvious effect on DNA fragmentation. 
However, dose-dependent increases in DNA fragmentation were 
observed in U937 cells treated with Mel-SHK, compared to cells treated 
with SHK alone (Fig. 1A). A combination of 0.75 μM SHK and 2 mM Mel 
exerted the most optimal effects on DNA fragmentation and cell viability 
(~50%; Fig. 1B and C) and disrupted cell morphology (phase-contrast 
microscopy; Fig. S1A). Combination Index (CI) values were calculated 
and depicted in Fig. 1D; CI values < 1 are considered to be synergistic. 
The promotion of SHK by Mel was observed, since a 1.84-fold shift for 
SHK was observed in the IC50 shift assay (Fig. S1B). To understand the 
timing of Mel treatment on cancer cell sensitization, we evaluated the 
effect of pre-treatment of the cells with Mel (0.5, 1, 2 mM) for 1 h fol-
lowed by SHK (0.75 μM for U937 and 3 μM for HeLa) treatment. For both 
the cell types, cell viability was reduced significantly and dose- 
dependently (Fig. S1C). In addition, we compared the differences in 
cell viability after Mel pre-treatment followed by SHK treatment, versus 
simultaneous Mel and SHK treatment. The results showed that, when 
compared to combined treatment, pre-treatment of Mel for 1 h followed 
by SHK has almost similar effects on cancer cell sensitisation. For both 
U937 and HeLa cells, the reduction in cell viability was the same without 
any significant difference amongst the two ways of treatment (Fig. S1D). 
Hence, for further experiments only the combination treatment was 
used. 
Mel-SHK significantly enhanced apoptosis, as evidenced by an in-
crease in Annexin V-FITC-positivity and sub-G1 phase accumulation of 
approximately 30% vs. SHK treatment alone (Fig. 1E and F). Activation 
of apoptosis-related proteins and ROS generation are key apoptosis 
triggers [24]. Mel-SHK treatment for 1 h showed a sharp increase in the 
levels of ROS production (Fig. 1G), which was associated with a sig-
nificant decrease in SIRT3/SOD2 expression and a decrease in relative 
SOD2 activity compared with SHK alone (Fig. 1H and I). Additionally, 
Mel-SHK treatment induced mitochondrial calcium overload and an 
increased number of cells with a low MMP over time (Fig. 1J and K). 
Furthermore, combined treatment also inhibited Bcl-xL expression, 
enhanced Bax expression, and induced caspase-3 cleavage in U937 cells 
(Fig. 1L). 
3.2. Mel-SHK-induced cytotoxicity and caspase activation in solid cancer 
cell lines 
Mel-SHK treatment induced a significant, dose-dependent reduction 
in cell viability and enhanced cytotoxicity in 4 solid cancer cell lines 
(AGS, MCF7, SW480, and HeLa; Fig. 2A–D), but exerted less significant 
effects in HepG2 and A549 cells (Fig. 2E and F). We also calculated the 
CI values, and the CI theorem of Chou-Talalay offers quantitative defi-
nition for additive effect (CI ¼ 1), synergism (CI < 1), and antagonism 
(CI > 1) in drug combinations (Fig. 2 A–F). Furthermore, the promotion 
of SHK by Mel was further demonstrated using IC50 shift assay, as shown 
in Fig. S2A. Additionally, Mel-SHK upregulated the levels of cleaved 
caspase-3 and/or PARP in AGS, MCF7, and SW480 cells (Fig. 2G–I). 
HeLa cells, which are the oldest and most commonly used human cell 
line [25], were selected for a detailed analysis of the pathways involved 
in Mel-SHK-induced cancer cell death in later experiments. 
3.3. Mel- SHK-induced cell growth inhibition and apoptosis in HeLa cells 
To understand the anti-cancer properties of Mel sensitised SHK, 
several aspects of carcinogenesis were investigated. We confirmed that 
Mel (0–2 mM) potentiates the deleterious effects of SHK (3 μM) on 
cancer cell viability and increases cytotoxicity in a dose-dependent 
manner (Fig. 3A and B) via phase-contrast microscopy (Fig. S2B and 
C). We conducted a clonogenic assay for up to 10 days after treatment to 
evaluate the long-term effects of Mel-SHK on cancer cell survival. 
Notably, the number of cells, as well as the sizes of colonies in Mel-SHK- 
treated groups, appeared fewer and smaller, respectively, compared 
with Mel or SHK individual treatment, further confirming the anti- 
proliferative effect of this combination (Fig. 3C). Additionally, com-
bined treatment significantly increased apoptosis and sub-G1 phase 
accumulation (Fig. 3D and E). As shown in Fig. 3F, Mel-SHK treatment 
decreased the expression of CDC25C, an important cell cycle regulator 
[26], and the dephosphorylation of cdc2 (Tyr15) and CHK1. Although 
p-Rb (Ser795) downregulation was noted in Mel-SHK-treated cells, no 
change in the p-P53 level was observed. 
We also used a wound healing assay to assess the effect of Mel-SHK 
on cell migration. Combined treatment significantly inhibited HeLa cell 
migration, as indicated by an approximately 60% reduction in scratch 
width vs. approximately 80% and 90% reductions in SHK- and Mel- 
treated cells at 72 h post treatment (Fig. 3G). We further determined 
that Mel-SHK significantly inhibited the expression of matrix 
metalloproteinases-2 (MMP-2) and MMP-9, which are strongly associ-
ated with cancer metastasis (Fig. 3H) [27]. 
Next, we analysed apoptosis-related proteins by western blotting to 
investigate the effect of Mel-SHK on apoptotic HeLa cell death. Notably, 
combined treatment downregulated the anti-apoptotic proteins Bcl-xL 
and XIAP while promoting caspase-3 and PARP cleavage, suggesting 
the initiation of caspase-mediated apoptosis. Mel-SHK co-treatment also 
significantly downregulated UHRF1, a major factor in the G1/S phase 
transition and DNA damage checkpoint (Fig. 3I) [28]. 
Fig. 1. The melatonin-shikonin (Mel-SHK) combination exerts strong anti-cancer activities and downregulates SIRT3/SOD2 in U937 cells. U937 cells were 
treated with melatonin (Mel, 0–2 mM) or shikonin (SHK, 0–0.9 μM) alone or in combination for 6 h unless otherwise indicated. (A) DNA fragmentation was assessed. 
The histogram depicts the percentage of DNA fragmentation in cells treated with SHK alone (white bars) or in combination with Mel at various concentrations. The 
effects of SHK (0.75 μM) and concomitant dose-dependent effect of Mel (0–2 mM) were investigated with respect to (B) DNA fragmentation, (C) cell viability, (D) 
Combination Index (CI), (E) apoptosis [Annexin V/propidium iodide (PI) double-staining] and (F) hypodiploid (sub-G1) DNA content. (G) Cells with high levels of 
reactive oxygen species (ROS) were evaluated at 1 h and 3 h post-treatment. (H) SOD2 and SIRT3 protein expression levels were analysed by western blotting 1 h 
after treatment with Mel and SHK alone or in combination. The bar graph depicts the relative expression levels compared to SHK treatment alone. (I) Relative 
analysis of SOD2 activity. (J) Mitochondrial calcium (Ca2þ) levels at 1 h and (K) mitochondrial membrane potential (MMP) at 4 h, 5 h and 6 h post-treatment. (L) 
Western blotting analysis of pro-apoptotic and anti-apoptotic protein expression. Flow cytometry data are presented as histograms and bar graphs. Relative protein 
expression was calculated for all western blots, using actin for normalisation and as a loading control. One representative figure from at least three independent 
experiments is shown for each assay. The data in each bar graph are presented as the means � standard errors of the means (SEM). *P < 0.05, **P < 0.01, and ***P <
0.001 relative to SHK treatment alone. 
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Fig. 2. Treatment with melatonin-shikonin (Mel-SHK) enhances cytotoxicity and caspase activation in solid cancer cell lines. (A) AGS, (B) MCF7, (C) 
SW480, (D) HeLa, (E) HepG2, and (F) A549 cells were treated with Mel and/or SHK at various concentrations. Caspase 3 and/or PARP cleavage was investigated in 
(G) AGS, (H) MCF7 and (I) SW480 cells. In all experiments, the treatment duration was 24 h. The relative protein expression was calculated, and one representative 
figure from at least three independent experiments is shown. Actin was used for normalisation and as a loading control. The data in each bar graph are presented as 
the means � SEM (n ¼ 3). ns: not significant, *P < 0.05 and ***P < 0.001 relative to SHK treatment alone. 
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3.4. Mel-SHK induces ROS production and SIRT3/SOD2 pathway 
inhibition 
Various intracellular signals, including oxidative stress, can trigger 
apoptosis. Mel-SHK strongly induced ROS production in HeLa cells 
compared with Mel or SHK alone (Fig. 4A), and this increase was 
associated with significant downregulation of the antioxidant proteins 
Gpx1, HO-1, and SOD2, as well as the deacetylase SIRT3 (Fig. 4B) [29]. 
Additionally, we showed that not just the expression but also the activity 
of SOD2 was significantly inhibited in Mel-SHK-treated HeLa cells 
(Fig. 4C), immunofluorescence confirmed the reduced expression of 
SOD2 and SIRT3 in nearly all cells subjected to combined treatment 
(Fig. 4D and E). In contrast, in normal cells, melatonin is known to 
upregulate the expression of SIRT3-SOD2 to reduce the oxidative dam-
age [30–32]. To confirm that the responses of cancer cells to Mel 
treatment is the opposite of its effects in normal cells, we examined the 
effect of Mel treatment in normal cells (BHK, Vero, NIH3T3, and HaCaT) 
under oxidative stress. Our results showed that Mel treatment over-
comes the toxic effects of hydrogen peroxide (H2O2) by increasing cell 
viability and decreasing ROS generation (Fig. S3), indicating the pro-
tective effects of Mel in all the normal cell types studied. 
Furthermore, calcium can modulate the induction of apoptosis [33], 
although mitochondrial calcium was not influenced by Mel or SHK 
treatment, we observed a sharp increase in the number of cells with high 
mitochondrial free calcium after Mel-SHK treatment (Fig. 4F). Mel-SHK 
co-treatment also further downregulated the MMP, compared with SHK 
alone (Fig. 4G). 
3.5. Mel-SHK induces ER stress and MAPK/Erk and AKT pathway 
dysregulation 
As ER stress induces apoptosis and activates stress kinases [34], we 
explored whether Mel and SHK could lead to ER stress in HeLa cells. 
Mel-SHK significantly increased the expression of the ER stress markers 
CHOP and GRP78 after 12 h (Fig. 5A). Signalling pathways regulating 
apoptosis crucially require mitogen-activated protein kinases (MAPKs) 
such as c-Jun-N-terminal kinase (JNK), extracellular signal-regulated 
kinase (Erk), and p38. After Mel-SHK treatment, JNK and p38 phos-
phorylation increased significantly, while Erk phosphorylation was 
inhibited. The levels of total Erk, total JNK, and total p38 were unaf-
fected (Fig. 5B). The AKT signalling pathway is a known regulator of ER 
stress, and the inhibition of ER stress-induced AKT signalling is impor-
tant to cancer cell survival and anti-cancer treatment resistance 
[34–36]. The kinase PDK1 is an upstream activator of AKT, while the 
phosphorylation of PKCδ is a downstream target of AKT [37]. We 
showed that Mel-SHK treatment induced AKT and PDK1 dephosphory-
lation but increased PKCδ phosphorylation, without affecting the total 
AKT levels (Fig. 5C). 
3.6. Caspase and ER stress inhibitors rescue cell death while PI3K 
inhibitor enhances Mel-SHK-induced cytotoxicity 
Specific pathway inhibitors were used to determine the roles of 
MAPK and AKT signalling pathways in Mel-SHK-treated HeLa cells. Pre- 
treatment with Z-VAD-FMK, a pan-caspase inhibitor, neutralised Mel- 
SHK-induced cancer cell toxicity (Fig. 6A), reduced PARP cleavage, 
increased colony formation, and reduced sub-G1 phase accumulation 
(Fig. 6B–D). Similarly, ER-stress inhibitor (4-PBA) pre-treatment 
significantly reduced cytotoxicity, caspase-3 cleavage, and sub-G1 
phase accumulation (Fig. 6E–G). In contrast, a JNK inhibitor 
(JNK–IN–8) and p38 inhibitor (SB203580) failed to exert protective 
effects against Mel-SHK treatment (Fig. S4A and B). Interestingly, pre- 
treatment with LY 294002 (PI3K/AKT inhibitor) had a further aggre-
gative effect on cytotoxicity, colony formation, and apoptosis, as evi-
denced by increased PARP cleavage and sub-G1 phase accumulation 
(Fig. 6H–K). U0126 (MEK-1/2 inhibitor) pre-treatment had a slight but 
non-significant effect on cytotoxicity and anti-clonogenicity (Fig. S4C). 
These data suggest a downstream role for AKT signalling in Mel-SHK- 
induced cell death. 
3.7. NAC rescues HeLa cells from the anti-cancer effects of Mel-SHK 
We subsequently treated HeLa cells with NAC, a direct antioxidant 
and ROS scavenger [38], to confirm the Mel-SHK-induced anti-cancer 
effects were due to increased ROS production and oxidative stress. 
Pre-treatment with NAC significantly reduced the cytotoxic effects of 
Mel-SHK (Fig. 7A), which was confirmed by an assessment of cell 
morphology (Fig. S2D). Colony formation assay showed that cell death 
in Mel-SHK-treated HeLa cells was prevented by NAC pre-treatment, 
facilitating long-term survival (Fig. 7B), and the populations of both 
early and late apoptotic cells were significantly reduced (Fig. 7C). NAC 
also inhibited the Mel-SHK-induced sub-G1 phase cell accumulation, 
leading to an increased shift to the G0/G1 phase and upregulated 
CDC25C and p-cdc2 levels (Fig. 7D and S2E). Likewise, NAC further 
rescued the inhibitory effect of Mel-SHK on cell migration, as indicated 
by a substantial reduction in the open areas of a wound assay (Fig. 7E). 
Consistent with these findings, NAC reversed the Mel-SHK-mediated 
inhibition of MMP-2 and MMP-9 (Fig. 7F). Furthermore, 
Mel-SHK-induced cleavage of caspase-3 and PARP were completely 
inhibited by the pre-treatment of NAC in HeLa cells (Fig. 7G). Addi-
tionally, we showed that the protective effects of NAC against Mel-SHK 
were not specific to HeLa cells, as NAC pre-treatment had anti-apoptotic 
effects, particularly the reversal of caspase-3 and/or PARP cleavage, in 
MCF7, AGS, and SW480 cells (Fig. 7H–J). These effects are consistent 
with the inhibition of Mel-SHK-induced ROS generation by NAC 
(Fig. 7K). 
Next, we investigated the effect of NAC pre-treatment on Mel-SHK- 
induced ER stress, and the MAPK and AKT pathways. In Mel-SHK- 
treated HeLa cells, NAC pre-treatment upregulated antioxidant pro-
teins (Gpx1, HO-1, SOD2) and SIRT3, as well as SOD2 activity (Fig. 7L 
and M), and significantly reduced the numbers of cells with mitochon-
drial calcium overload and low MMP (Fig. 7N and O). NAC also signif-
icantly suppressed the Mel-SHK-induced expression of CHOP and GRP78 
(Fig. 7P) and reduced the effects of the drug combination on Erk, p38, 
and JNK phosphorylation (Fig. 7Q). NAC pre-treatment further reversed 
the Mel-SHK-induced dephosphorylation of AKT and PDK1, while 
inducing the dephosphorylation of PKCδ (Fig. 7R), thus overcoming the 
AKT activation loop and ER stress. 
3.8. The adverse effects of Mel-SHK on HeLa cells are inhibited by SIRT3 
SIRT3 binds directly to SOD2 and regulates SOD2 activity [15], the 
Fig. 3. Melatonin-shikonin (Mel-SHK) treatment inhibits HeLa cell growth and facilitates apoptosis. (A) Cell viability and (B) cytotoxicity were assessed in 
HeLa cells treated with SHK (3 μM) with or without Mel (0–2 mM). The effects of combined Mel-SHK treatment at these concentrations on (C) clonogenicity, (D) 
apoptosis [Annexin V/PI double-staining] and (E) sub-G1 phase accumulation were then evaluated. (F) Western blotting was used to identify the levels of several 
proteins associated with cell division and cell cycle. (G) A wound-healing assay was performed to investigate the effects of treatment on cell migration. The bar graph 
depicts the percentage of the open area remaining after treatment. Western blotting was further performed to evaluate (H) the levels of matrix metalloproteinases 
(MMPs) and (I) pro- and anti-apoptotic proteins in response to Mel-SHK treatment. For all experiments, the treatment duration was 24 h. Flow cytometry data are 
presented as histograms and bar graphs. Relative protein expression was calculated for all western blots, using actin for normalisation and as a loading control. One 
representative figure from at least three independent experiments is shown for each assay. The data in each bar graph are presented as the means � SEM. *P < 0.05, 
**P < 0.01, and ***P < 0.001 relative to SHK treatment alone. 
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immunoprecipitation of SOD2 revealed a dramatic decrease in 
SIRT3–SOD2 binding in cells treated with Mel-SHK, but not with indi-
vidual drug (Fig. 8A). To determine the role of SIRT3 in 
Mel-SHK-induced cell death, HeLa cells were pre-treated with 4-BR, a 
broad-spectrum SIRT inhibitor. Although 50 μM 4-BR treatment alone 
had no effect, subsequent Mel-SHK treatment led to further increases in 
caspase-3 cleavage, sub-G1 phase accumulation and MMP losses, 
compared to Mel-SHK treatment (Fig. 8B–D). 
To further confirm the role of decreased SIRT3-SOD2 expression in 
Mel-SHK-induced cancer cell death, HeLa cells were transfected with 
SIRT3-expressing plasmids (Fig. 8E). In response to Mel-SHK, these 
SIRT3-overexpressing cells exhibited a significant reduction in sub-G1 
cell accumulation, as well as reduced PARP cleavage and ROS genera-
tion, concomitant with increased SOD2 expression (Fig. 8F–I). In addi-
tion, SIRT3 overexpression significantly reduced the fractions of cells 
with mitochondrial free calcium and a low MMP induced by Mel-SHK 
treatment (Fig. 8J and K). Moreover, SIRT3 overexpression also inhibi-
ted the expression of CHOP and GRP78 (Fig. 8L) and reversed the levels 
of proteins associated with MAPK and AKT signalling pathways in Mel- 
SHK-treated HeLa cells (Fig. 8M and N). These results suggest that SIRT3 
inhibition is the key factor in the effects of Mel-SHK on oxidative stress, 
ER stress, apoptosis, and cell growth via SIRT3/SOD2 and AKT pathway 
inhibition. 
4. Discussion 
In recent studies, cancers that were initially resistant to chemo-
therapy became sensitive when conventional drugs were combined with 
Mel [39,40]. However, few studies identified a common target molecule. 
In this study, we demonstrated for the first time that Mel sensitised 
SHK-induced cancer cell cytotoxicity by inhibiting SIRT3/SOD2 
expression and SOD2 activity. Mel-SHK treatment promoted apoptosis 
and induced ER stress, leading to AKT inactivation via increased ROS 
production in various cancer cell types (Fig. 9), suggesting the broad 
chemotherapeutic potential of the Mel-SHK combination and the 
SIRT3/SOD2-AKT pathway as a novel drug target. 
SOD2, an antioxidant enzyme and important regulator of mito-
chondrial redox balance, is deacetylated by SIRT3, leading to enhanced 
antioxidant activity and decreased ROS generation [41]. Previously, 
SIRT3 downregulation, decreased SOD2 activity, and increased ROS 
Fig. 4. Melatonin-shikonin (Mel-SHK) treatment enhances reactive oxygen species (ROS) generation and inhibits SIRT3/SOD2 pathway activation in HeLa 
cells. (A) The levels of ROS in HeLa cells treated with Mel-SHK for 6 h are presented as fractions of cells with high ROS. (B) The levels of key antioxidant proteins 
(Gpx1, HO-1, and SOD2) and SIRT3 and (C) relative SOD2 activity were measured at 12 h post-treatment. The protein expression of (D) SOD2 and (E) SIRT3 in these 
cells was confirmed using immunofluorescence by confocal microscopy. (F) The levels of mitochondrial free calcium (Ca2þ) and (G) MMP were measured in these 
cells at 12 h and 24 h post-Mel-SHK treatment, respectively. All experiments used SHK at 3 μM and Mel at 0–2 mM. Flow cytometry data are presented as histograms 
and bar graphs. Relative protein expression was calculated for all proteins in the western blots and actin was used for normalisation and as a loading control. One 
representative figure from at least three independent experiments is shown for each assay. The data in each bar graph are presented as the means � SEM. *P < 0.05, 
**P < 0.01, and ***P < 0.001 relative to SHK treatment alone. 
Fig. 5. Melatonin-shikonin (Mel-SHK) treatment enhances endoplasmic reticulum (ER) stress and MAPK and AKT pathway dysregulation in HeLa cells. 
(A) Western blot analysis of the specific ER stress-related proteins, CHOP and GRP78 and (B) the levels and activation (i.e., phosphorylation) of ERK, p38, and JNK. 
(C) Quantitative Western blot analysis to determine the activation of the AKT pathway components p-AKT, p-PDK1, and p-PKC, as well as total AKT. Relative protein 
expression was calculated for all proteins in the western blots. Actin was used for normalisation and as a loading control. One representative figure from at least three 
independent experiments is shown for each assay. The data in each bar graph are presented as the means � SEM. *P < 0.05, **P < 0.01, and ***P < 0.001 relative to 
SHK treatment alone. 
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Fig. 6. Effects of a pan-caspase inhibitor (Z-VAD-FMK), endoplasmic reticulum (ER) stress inhibitor (4-PBA) and PI3K inhibitor (LY 294002) in melatonin- 
shikonin (Mel-SHK)-treated HeLa cells. (A) Cytotoxicity, (B) PARP cleavage, (C) clonogenicity, and (D) sub-G1 phase accumulation were determined after pre- 
treatment with Z-VAD-FMK. (E) Cytotoxicity, (F) caspase-3 cleavage, and (G) sub-G1 phase accumulation were also determined in cells pre-treated with 4-PBA. 
(H) Cytotoxicity, (I) PARP cleavage, (G) clonogenicity, and (K) sub-G1 phase accumulation were determined in cells pre-treated with LY 294002 to determine 
the involvement of the AKT pathway in Mel-SHK-induced cancer cells. Flow cytometry data are presented as histograms and bar graphs. Relative protein expression 
was calculated for all the proteins in western blots. Actin was used for normalisation and as a loading control. One representative figure from at least three inde-
pendent experiments is shown for each assay. The data in each bar graph are presented as the means � SEM. #P < 0.05, ##P < 0.01, and ###, P < 0.001 relative to 
Mel-SHK treated cells. 
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Fig. 7. Effects of the reactive oxygen species (ROS) scavenger, NAC, on the anti-cancer effects of melatonin-shikonin (Mel-SHK) in HeLa, MCF7, AGS, and 
SW480 cells. HeLa cells were pre-treated with NAC followed by Mel-SHK. The effects on (A) cytotoxicity, (B) clonogenicity, (C) apoptosis [Annexin V/PI double- 
staining], (D) sub-G1 area, and (E) cell migration were evaluated to confirm the role of ROS. (F) Western blotting was performed to analyse the levels of specific 
proteins related to cell migration, such as matrix metalloproteinase-2 (MMP2) and MMP9. The protective effects of NAC against Mel-SHK-induced apoptosis including 
caspase-3 and/or PARP cleavage, were determined in (G) HeLa, (H) MCF7, (I) AGS and (J) SW480 cells. The ability of NAC to reverse Mel-SHK-mediated (K) ROS 
generation, (L) oxidative stress-related protein expression, (M) SOD2 activation, (N) mitochondrial calcium (Ca2þ) accumulation, (O) MMP losses and (P) ER-stress 
related protein expression were also investigated. (Q, R) Western blot analysis of the effects of NAC on the expression of MAPK and AKT pathway-related proteins in 
Mel-SHK-treated cells. The Mel-SHK treatment duration was 24 h for all experiments except those described in B (10 days), K (6 h) and L, M, N, P, Q and R (12 h). 
Relative protein expression was calculated for all the proteins in western blots. Actin was used for normalisation and as a loading control. Flow cytometry data are 
presented as histograms and bar graphs. One representative figure from at least three independent experiments is shown for each assay. The data in each bar graph 
are presented as the means � SEM. #P < 0.05, ##P < 0.01, and ###P < 0.001 relative to Mel-SHK treated cells. 
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production were found to contribute to the anti-tumour effects of 
linalool against glioma [42]. Similarly, we showed that Mel-SHK 
inhibited SOD2 activity and increased the fraction of cells with high 
ROS levels, which led to increases in mitochondrial calcium levels, MMP 
disruption, and apoptosis in various cancer cells. All these effects were 
reversed by treatment with a ROS scavenger, suggesting that excessive 
oxidative stress plays a key role in Mel-SHK-induced cytotoxicity in 
cancer cells. Several studies have reported that Mel treatment induces 
cell death in cancer cells but has beneficial effects on normal cells 
[30–32,43,44]. This is probably because Mel induces the release of 
mitochondrial cytochrome C, leading to apoptosis in cancer cells [45]. 
Also, Mel treatment in cancer cells is known to interact with mito-
chondrial ROS forming a range of metabolites such as N-acetylserotonin, 
which can induce apoptosis. However, this phenomenon does not occur 
in normal cells [3]. Hence, the difference in Mel metabolism between 
normal and tumour cells is beneficial to the chemotherapy, which causes 
severe side effects to normal cells. In this study, we also showed that Mel 
potentiated the efficiency of SHK-induced cancer cell cytotoxicity and, 
at the same time, protected normal cells from oxidative stress. 
Tumour cells characteristically exhibit a loss of control of the balance 
between proliferation and death. Interventional cancer therapies aim to 
steer this balance towards the induction of apoptotic cell death, a pro-
cess prevented by Bcl-2 and Bcl-xL but promoted by Bak and Bax, which 
activate pro-apoptotic signals, and caspase activation and cleavage [46]. 
In a previous report, SHK stimulated apoptosis in squamous cell carci-
noma cells by downregulating Bcl-2, upregulating Bax, and inducing 
Fig. 7. (continued). 
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caspase-3 cleavage [47]. Similarly, Cucina et al. reported that 
Mel-induced apoptosis activated caspases, cleaved PARP, and concom-
itantly decreased the Bcl-2/Bax ratio in breast cancer cells [48]. 
Consistent with those findings, we demonstrated that Mel-SHK combi-
nation therapy had significant pro-apoptotic effects in HeLa cells, which 
was counteracted by a pan-caspase inhibitor. 
Lin et al. recently reported that a combination of Mel and sorafenib 
inhibited hepatocellular carcinoma cell growth and apoptosis via the 
JNK pathway in a dose-dependent manner [49]. When used 
co-operatively, Mel and SHK exert an enhanced anticancer effect 
mediated by apoptotic cell death in various cancer cells in correlation 
with caspase 3 activation, PARP cleavage, and JNK pathway activation. 
However, a JNK inhibitor did not block the apoptosis induced by 
Mel-SHK. As the JNK pathway is activated by high ROS levels [50], we 
believe that the JNK inhibitor was not strong enough to overcome the 
effects of ROS-mediated JNK pathway activation induced by Mel-SHK. 
The combination of Mel-SHK might enhance cancer cell death by 
regulating oxidative stress. We also evaluated the potential involvement 
of other types of pathways, such as necroptosis, in Mel-SHK-induced cell 
death by incubating HeLa cells with the novel and highly active nec-
roptosis inhibitors Necrostatin-1 (Nec-1, a specific inhibitor of RIP1 ki-
nase) and necrosulfonamide (NSA, a specific inhibitor of necrosis 
downstream of RIP3 activation). Nec-1 pre-treatment appeared to 
inhibit cytotoxicity and restored colony formation in Mel-SHK-treated 
cells, whereas NSA pre-treatment had no such protective effects 
(Fig. S4D and E). Accordingly, we are currently exploring the potential 
involvement of necroptosis and RIP1, but not RIP3, as a key factor in 
Mel-SHK-induced cell death. 
Evidences suggest that ER stress inhibition favours cancer cell sur-
vival and enhances chemotherapeutic resistance [51,52]. Prolonged and 
severe ER stress can have a cytotoxic effect by activating mechanisms 
involved in apoptotic cell death. Mel, when combined with several other 
chemotherapeutic drugs, has shown its utility in cancer treatment by 
modulating ER stress via the Erk/MAPK and AKT pathways [53]. 
Furthermore, in colon cancer, SHK-induced cell death appears to be 
mediated by ER stress activation via MAPK signalling [54,55]. Here, we 
demonstrated that the combination of Mel and SHK strongly induced ER 
stress and cancer cell death, possibly by regulating the MAPK and AKT 
pathways in these cells. Moreover, pre-treatment with an ER stress in-
hibitor reduced the cytotoxicity associated with Mel-SHK treatment in 
HeLa cells, whereas PI3K/AKT inhibitor treatment further intensified 
the cytotoxicity and sub-G1 phase accumulation. 
In conclusion, our results suggested that the onco-static and cyto-
toxic effects of Mel-SHK combination therapy are likely due to SIRT3/ 
SOD2-AKT pathway inhibition. We further suggest that SIRT3-SOD2 
acts as a master regulator of key cellular processes required for cancer 
cell survival. Thus, the Mel-SHK-induced inhibition of these molecules 
may represent a novel chemotherapeutic approach. We recommend the 
consideration of this powerful drug combination as a potential chemo-
therapeutic candidate for in vivo studies and as an adjuvant therapy in 
clinical trials. 
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